165 related articles for article (PubMed ID: 23802147)
1. Novel application of polioviral capsid: development of a potent and prolonged oral calcitonin using polioviral binding ligand and Tat peptide.
Manosroi J; Lohcharoenkal W; Götz F; Werner RG; Manosroi W; Manosroi A
Drug Dev Ind Pharm; 2014 Aug; 40(8):1092-100. PubMed ID: 23802147
[TBL] [Abstract][Full Text] [Related]
2. Polioviral receptor binding ligand: a novel and safe peptide drug carrier from polioviral capsid.
Manosroi J; Lohcharoenkal W; Götz F; Werner RG; Manosroi W; Manosroi A
Drug Deliv; 2012 Jan; 19(1):21-7. PubMed ID: 22142037
[TBL] [Abstract][Full Text] [Related]
3. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide.
Manosroi J; Lohcharoenkal W; Götz F; Werner RG; Manosroi W; Manosroi A
Drug Dev Ind Pharm; 2013 Apr; 39(4):520-5. PubMed ID: 22564052
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery.
Prego C; Fabre M; Torres D; Alonso MJ
Pharm Res; 2006 Mar; 23(3):549-56. PubMed ID: 16525861
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin.
Cheng W; Lim LY
Mol Pharm; 2008; 5(4):610-21. PubMed ID: 18481870
[TBL] [Abstract][Full Text] [Related]
6. Potent enhancement of GFP uptake into HT-29 cells and rat skin permeation by coincubation with tat peptide.
Lohcharoenkal W; Manosaroi A; Götz F; Werner RG; Manosroi W; Manosaroi J
J Pharm Sci; 2011 Nov; 100(11):4766-73. PubMed ID: 21681754
[TBL] [Abstract][Full Text] [Related]
7. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).
Sinko PJ; Lee YH; Makhey V; Leesman GD; Sutyak JP; Yu H; Perry B; Smith CL; Hu P; Wagner EJ; Falzone LM; McWhorter LT; Gilligan JP; Stern W
Pharm Res; 1999 Apr; 16(4):527-33. PubMed ID: 10227707
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin.
Aguirre TA; Rosa M; Coulter IS; Brayden DJ
Eur J Pharm Sci; 2015 Nov; 79():102-11. PubMed ID: 26349051
[TBL] [Abstract][Full Text] [Related]
9. PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery.
Licciardi M; Pasut G; Amato G; Scialabba C; Mero A; Montopoli M; Cavallaro G; Schiavon O; Giammona G
Eur J Pharm Biopharm; 2013 May; 84(1):21-8. PubMed ID: 23275110
[TBL] [Abstract][Full Text] [Related]
10. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy.
Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC
J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery.
Lee HE; Lee MJ; Park CR; Kim AY; Chun KH; Hwang HJ; Oh DH; Jeon SO; Kang JS; Jung TS; Choi GJ; Lee S
J Control Release; 2010 Apr; 143(2):251-7. PubMed ID: 20026364
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol.
Cheng W; Lim LY
J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs.
Fan T; Chen C; Guo H; Xu J; Zhang J; Zhu X; Yang Y; Zhou Z; Li L; Huang Y
Eur J Pharm Biopharm; 2014 Oct; 88(2):518-28. PubMed ID: 24968819
[TBL] [Abstract][Full Text] [Related]
14. Application of the yeast-surface-display system for orally administered salmon calcitonin and safety assessment.
Sun PN; Zhang XC; Chen YS; Zang XN
Biotechnol Prog; 2010; 26(4):968-74. PubMed ID: 20730756
[TBL] [Abstract][Full Text] [Related]
15. Potent and prolonged hypoglycemic activity of an oral insulin--Tat mixture in diabetic mice.
Manosroi J; Tangjai T; Werner RG; Götz F; Manosroi W; Manosroi A
Drug Res (Stuttg); 2013 Jul; 63(7):351-6. PubMed ID: 23539426
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
17. Flash Fabrication of Orally Targeted Nanocomplexes for Improved Transport of Salmon Calcitonin across the Intestine.
Sun L; Le Z; He S; Liu J; Liu L; Leong KW; Mao HQ; Liu Z; Chen Y
Mol Pharm; 2020 Mar; 17(3):757-768. PubMed ID: 32011888
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
du Plessis LH; Lubbe J; Strauss T; Kotzé AF
Int J Pharm; 2010 Jan; 385(1-2):181-6. PubMed ID: 19854253
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
20. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery.
Chen M; Li XR; Zhou YX; Yang KW; Chen XW; Deng Q; Liu Y; Ren LJ
Peptides; 2009 Jul; 30(7):1288-95. PubMed ID: 19540427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
